Abstract 1055P
Background
Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. We previously modified T cells with a tumor-penetrating peptide iRGD (SmarT cells), and demonstrated that SmarT cells promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells. We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 1.0 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection.
Results
Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated, solid cancers.
Clinical trial identification
The trial protocol number is ChiCTR2200061306 and the release date 20 June 2022.
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of Nanjing Drum Tower Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1070P - Patterns of adverse reactions for immune checkpoint inhibitors in cancer patients with central nervous system metastases
Presenter: Tianqi Gu
Session: Poster session 19
1071P - Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database
Presenter: Zimu Li
Session: Poster session 19
1072P - DuoBody-EpCAMx4-1BB mediates conditional T cell co-stimulation and promotes antitumor activity in preclinical models
Presenter: Sina Fellermeier-Kopf
Session: Poster session 19
1073P - Overcoming resistance to immunotherapy with FGFR inhibition in GU cancer models
Presenter: Ilya Tsimafeyeu
Session: Poster session 19
1074TiP - A phase I/II, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors
Presenter: Martin Gutierrez
Session: Poster session 19
1075TiP - A phase I/Ib open-label, first-in-human, single agent, dose escalation and expansion study of a HER2-targeted T cell engager (SAR443216) in patients with relapsed/refractory HER2-expressing solid tumors
Presenter: Ecaterina Dumbrava
Session: Poster session 19
1076TiP - First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors
Presenter: Sunil Babu
Session: Poster session 19
1077TiP - TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
Presenter: Harshabad Singh
Session: Poster session 19
1078TiP - Phase I/II, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101 (anti-VISTA) as monotherapy and in combination with cemiplimab in patients (pts) with advanced solid tumors
Presenter: Kyriakos Papadopoulos
Session: Poster session 19